Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and ...

Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk ...

Their Phase 2 MOMENTUM trial for obesity demonstrated significant ... Thus, despite its concentration, regulatory, and ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

The double-blinded, placebo-controlled study to assess safety and efficacy of R327G is set to begin mid-next month.

Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...

The Children’s Inn at NIH, a private nonprofit that supports kids in clinical trials, just broke ground on a long-planned ...

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...

In the phase 3 KOMET trial, Koselugo delivered a statistically significant ... The MEK 1/2 inhibitor endured several clinical ...